右旋布洛芬治疗幼年特发性关节炎患儿的疗效观察

doi:10.3969/j.issn.1671-7171.2022.03.015

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1131 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy and safety of dexibuprofen in children with juvenile idiopathic arthritis (JIA) and the expression of serum pain mediators and inflammatory factors. 【Methods】A total of 84 patients with JRA in our hospital were selected as the research objects and they were randomly divided into two groups, with 42 cases in the control group and 42 cases in the observation group. The control group was treated with naproxen, while the study group was treated with dexibuprofen for 2 weeks. The juvenile arthritis disease activity scale (JADAS27) was used to assess the improvement of clinical symptoms and physical signs before and after treatment. The serum pain mediators [serotonin (5-HT) and prostaglandin E2 (PGE2), slow excitation peptide bradykinin (BK), neuropeptide Y (NPY)] and inflammatory factor [tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), interleukin 17 (IL-17), matrix metalloproteinases-3(MMP-3)] expression levels were compared between the two groups as well. The incidence of adverse reactions were also compared. 【Results】The total effective rate of the observation group was 85.71%, which was significantly higher than 64.29% of the control group (P<0.05). The scores of each dimension and total score of JADAS27 in the two groups after treatment were significantly lower than those before treatment (all P<0.05), and the above indexes in the observation group after treatment were significantly lower than those in the control group after treatment (all P<0.05). The serum levels of 5-HT, PGE2, BK, NPY, TNF-α, IL-1, IL-17 and MMP-3 in the two groups after treatment were significantly lower than those before treatment (all P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (all P<0.05). The incidence of adverse reactions in the observation group was 4.76% (2/42), which was significantly lower than 19.05% (8/42) in the control group (P<0.05). 【Conclusion】The efficacy of dextral ibuprofen (dexibuprofen) in the treatment of JIA is remarkable, which can significantly improve the clinical symptoms and signs of children, inhibit the expression of inflammatory factors and pain-causing mediators, and has good safety.

Key words： Arthritis, Juvenile Ibuprofen/TU Treatment Outcome

Received: 17 June 2021

PACS:

R452

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Miao-miao
	ZHANG Kun

Cite this article:

ZHAO Miao-miao,ZHANG Kun. Efficacy and Safety of Dexibuprofen in Children with Juvenile Idiopathic Arthritis[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 374-377.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.03.015 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I3/374

[1] AESCHLIMANN F A,QUARTIER P. Juvenile idiopathic arthritis[J].Rev Prat,2019,69(2):188-194.
[2] 林基勇,庞宇舟,方刚,等. 基于GoPubMed类风湿关节炎发病机制的文献计量学分析[J].现代预防医学,2019,46(3):563-567.
[3] CIMAZ R,MAIOLI G,CLABRESE G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis[J].Expert Opin Biol Ther,2020,20(7):725-740.
[4] HALYABAR O,MEHTA J,RINGOLD S,et al. Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature[J].Paediatr Drugs,2019,21(6):469-492.
[5] PETTY R E,SOUTHWOOD T R,MANNERS P,et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision,Edmonton,2001[J].J Rheumatol,2004,31(2):390-392.
[6] MOURÃO A F,SANTOS M J,MELO-GOMES J,et al. Using the juvenile arthritis disease activity score based on erythrocyte sedimentation rate or C-reactive protein level: results from the portuguese[J].Arthritis Care Res (Hoboken),2014,66(4):585-591.
[7] 刘蕾,封其华. 幼年特发性关节炎病情评估方法研究进展[J].中华实用儿科临床杂志,2019,34(19):1516-1520.
[8] TOMIOKA R B,FERREIRA G R V,AIKAWA N E,et al. Non-steroidal anti-inflammatory drug induces luteinized unruptured follicle syndrome in young female juvenile idiopathic arthritis patients[J].Clin Rheumatol,2018,37(10):2869-2873.
[9] JACOBSON J L,PHAM J T. Juvenile idiopathic arthritis: a focus on pharmacologic management[J].J Pediatr Health Care,2018,32(5):515-528.
[10] CHOI Y,MIN K A,KIM C K. Development and evaluation of dexibuprofen formulation with fast onset and prolonged effect[J].Drug Dev Ind Pharm,2019,45(6):895-904.
[11] OKAMOTO N,YOKOTA S,TAKEI S,et al. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018[J].Mod Rheumatol,2019,29(1):41-59.
[12] 吴小川,李灿琳. 全身型幼年特发性关节炎发生机制及诊治策略[J].中华实用儿科临床杂志,2017,32(21):1607-1612.
[13] 谢彤,尹薇. 右旋布洛芬和萘普生在治疗儿童幼年特发性关节炎中的对照观察[J].中华实用儿科临床杂志,2020,35(21):1656-1658.